

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES  
PURSUANT TO SECTION 12(b) OR (g) OF THE  
SECURITIES EXCHANGE ACT OF 1934

**Virax Biolabs Group Limited**  
(Exact name of registrant as specified in its charter)

<b>Cayman Islands</b> (State of incorporation or organization)	<b>Not Applicable</b> (I.R.S. Employer Identification No.)
<b>30 Broadwick Street</b> <b>London</b> <b>United Kingdom</b> (Address of principal executive offices)	<b>W1F 8LX</b> (Zip Code)

Securities to be registered pursuant to Section 12(b) of the Act:

Title of each class to be so registered	Name of each exchange on which each class is to be registered
<b>Ordinary shares, par value US\$0.0001 per share</b>	<b>The Nasdaq Stock Market LLC</b>

If this Form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

If this Form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

If this Form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333-263694

Securities to be registered pursuant to Section 12(g) of the Act: **None**

**INFORMATION REQUIRED IN REGISTRATION STATEMENT**

**Item 1. Description of the Registrant's Securities to be Registered.**

A description of the securities of Virax Biolabs Group Limited, a Cayman Islands company limited by shares (the "Registrant"), to be registered hereunder is set forth under the heading "Description of Securities" in the prospectus constituting a part of the Registrant's Registration Statement on Form F-1 (File No. 333-263694), originally filed with the Securities and Exchange Commission (the "Commission") on December 23, 2021, as amended from time to time, which description is incorporated herein by reference. The description of such securities included in any form of prospectus subsequently filed by the Registrant with the Commission pursuant to Section 424(b) of the Securities Act of 1933, as amended, shall also be deemed to be incorporated herein by reference.

**Item 2. Exhibits.**

Pursuant to the "Instructions as to Exhibits" with respect to Form 8-A, no exhibits are required to be filed because no other securities of the Registrant are registered on the Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

**SIGNATURE**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

**Virax Biolabs Group Limited**

By: /s/ James Foster

James Foster

Chief Executive Officer

Dated: June 30, 2022

